A comprehensive review evaluated the therapeutic promise of targeted protein degradation (TPD) technologies and described potential health‑ and species‑level impacts of deploying degrading agents broadly. Authors summarized mechanisms—such as proteolysis targeting chimeras (PROTACs)—and discussed off‑target degradation risks, long‑term safety, and possible environmental persistence concerns. The review urges integrated assessment frameworks spanning preclinical toxicology, environmental fate studies and post‑marketing surveillance as the field scales. For biotech developers, the paper underscores the need for design strategies that maximize selectivity and for regulators to consider new risk paradigms for molecules that induce protein elimination rather than modulate activity.